Oxidative stress is intensely involved in enhancing the severity of various chronic respiratory diseases (CRDs) including asthma, chronic obstructive pulmonary disease (COPD), infections and lung cancer. Even though there are various existing anti-inflammatory therapies, which are not enough to control the inflammation caused due to various contributing factors such as anti-inflammatory genes and antioxidant enzymes. This leads to an urgent need of novel drug delivery systems to combat the oxidative stress. This review gives a brief insight into the biological factors involved in causing oxidative stress, one of the emerging hallmark feature in CRDs and particularly, highlighting recent trends in various novel drug delivery carriers including microparticles, microemulsions, microspheres, nanoparticles, liposomes, dendrimers, solid lipid nanocarriers etc which can help in combating the oxidative stress in CRDs and ultimately reducing the disease burden and improving the quality of life with CRDs patients. These carriers improve the pharmacokinetics and bioavailability to the target site. However, there is an urgent need for translational studies to validate the drug delivery carriers for clinical administration in the pulmonary clinic.

氧化应激强烈参与增强各种慢性呼吸道疾病（CRD）的严重程度，包括哮喘，慢性阻塞性肺疾病（COPD），感染和肺癌。即使存在各种现有的抗炎疗法，但仍不足以控制由于各种促发因素（例如抗炎基因和抗氧化酶）而引起的炎症。这导致迫切需要新颖的药物递送系统以对抗氧化应激。这篇评论简要介绍了引起氧化应激的生物学因素，这是CRD中新兴的标志性特征之一，特别是着重强调了各种新型药物递送载体的最新趋势，包括微粒，微乳剂，微球，纳米颗粒，脂质体，树状聚合物，固体脂质纳米载体等，可帮助对抗CRD中的氧化应激反应并最终减轻CRD患者的疾病负担并改善其生活质量。这些载体改善了对靶部位的药代动力学和生物利用度。但是，迫切需要进行转化研究以验证用于肺门诊所临床给药的药物递送载体。